Peer-reviewed veterinary case report
Reovirus treatment shows promise against canine histiocytic sarcoma
By Igase, Masaya et al.·Published in Veterinary and comparative oncology·2019·The United Graduate School of Veterinary Science, Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Anti-tumour activity of oncolytic reovirus against canine histiocytic sarcoma cells.
- Species:
- dog
Plain-English summary
A study found that reovirus, a type of virus, shows promise as a treatment for canine histiocytic sarcoma, a serious and aggressive cancer in dogs. Traditional treatments like lomustine often don't fully eliminate the tumors, so researchers explored reovirus as a new option. They discovered that reovirus can kill cancer cells and stop tumor growth in laboratory settings and in mice. This suggests that reovirus could be an effective treatment for dogs with this type of cancer, and further clinical trials are needed to explore its potential in pets.
People also search for: dog histiocytic sarcoma treatment · reovirus for dog cancer · lomustine effectiveness in dogs
Abstract
Canine histiocytic sarcoma is an aggressive, fatal neoplastic disease with a poor prognosis. Lomustine is generally accepted as the first-line systemic therapy, although this compound does not provide complete regression. Therefore, research into a novel approach against canine histiocytic sarcoma is needed. However, anti-tumour effects of oncolytic therapy using reovirus against histiocytic sarcoma are unknown. Here, we showed that reovirus has oncolytic activity in canine histiocytic sarcoma cell lines in vitro and in vivo. We found that reovirus can replicate and induce caspase-dependent apoptosis in canine histiocytic sarcoma cell lines. A single intra-tumoural injection of reovirus completely suppressed the growth of subcutaneously grafted tumours in NOD/SCID mice. Additionally, we demonstrated that susceptibility to reovirus-induced cell death was attributable to the extent of expression of type I interferons induced by reovirus infection in vitro. In conclusion, oncolytic reovirus appears to be an effective treatment option for histiocytic sarcoma, and therefore warrants further investigation in early clinical trials.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/30761736/